veralipride
Veralipride (Agreal, Agradil) is an atypical antipsychotic of the benzamide class. It is used for the treatment of vasomotor symptoms associated with menopause. It is a D2 receptor antagonist and it induces prolactin secretion without any estrogenic or progestagenic effects. It was first authorised for use in 1979. However, Veralipride has never gained approval in the United States.
Chemical data
- Formula
- C17H25N3O5S
- Molecular weight
- 383.5 g/mol
- IUPAC name
- 2,3-dimethoxy-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]-5-sulfamoylbenzamide
via PubChem
Drug data · ChEMBL
Withdrawn- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1979
- Indications
- psychosis, Hot flashes
via ChEMBL · EBI
Research
109 papers- The safety of veralipride.Expert opinion on drug safety · 2006
~1 min read
Article
2 sectionsContents
- See also
- References
Veralipride (Agreal, Agradil) is an atypical antipsychotic of the benzamide class. It is used for the treatment of vasomotor symptoms associated with menopause. It is a D2 receptor antagonist and it induces prolactin secretion without any estrogenic or progestagenic effects. It was first authorised for use in 1979. However, Veralipride has never gained approval in the United States.
The women who took it, in addition to extra-pyramidal effects, experienced an aggressive form of depression that resulted in death by suicide for some. The Sanofi laboratory, despite knowing its side effects, allowed women to continue taking it for a considerable amount of time. For this reason, its sale was banned in all countries except Mexico, which allowed its sale to continue for at least 15 years.
Available in 10 languages
via Wikidata sitelinks · CC0